NASDAQ:ARCT

Arcturus Therapeutics Stock Forecast, Price & News

$36.97
-0.03 (-0.08 %)
(As of 04/12/2021 03:45 PM ET)
Add
Compare
Today's Range
$35.12
Now: $36.97
$37.06
50-Day Range
$37.67
MA: $47.86
$66.98
52-Week Range
$15.04
Now: $36.97
$129.71
Volume34,239 shs
Average Volume1.24 million shs
Market Capitalization$971.57 million
P/E RatioN/A
Dividend YieldN/A
Beta3.01
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the treatment of liver and respiratory care diseases. The company engages in the discovery and development of RNA medicines, including the production of RNA drug substance and nanoparticle-formulated drug product; and development of infectious disease vaccines using its Self-Transcribing and Replicating RNA (STARR) technology. Its preclinical drug discovery and development programs include LUNAR-OTC development program that is developing mRNA compounds to treat ornithine transcarbamylase (OTC) deficiency; LUNAR-CF program, which is developing mRNA compounds to replace dysfunctional cystic fibrosis transmembrane conductance regulator (CFTR) protein in cystic fibrosis (CF) patients; and LUNAR-CV and LUNAR-MD that are internal research programs focused on target validation of multiple pipeline LUNAR-mRNA program candidates. The company owns LUNAR and nucleic acid technologies that are covered by a patent portfolio of 182 patents and patent applications, issued in the United States, China, Europe, Japan, and other countries. It has collaboration partnerships with Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for certain rare disease targets; Millennium Pharmaceuticals, Inc. (Takeda) to develop a nucleic acid-based therapeutic candidate for the treatment of nonalcoholic steatohepatitis; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus infection; CureVac AG; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19, a vaccine to address the Coronavirus outbreak; and Catalent, Inc. to support the expected manufacture of Arcturus' COVID-19 mRNA vaccine candidate (LUNAR-COV19. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
Arcturus Therapeutics logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ARCT
CUSIPN/A
Phone858-900-2660
Employees118
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$20.79 million
Book Value$1.70 per share

Profitability

Net Income$-25,990,000.00
Net Margins-506.70%

Miscellaneous

Market Cap$971.57 million
Next Earnings Date5/6/2021 (Estimated)
OptionableOptionable

Headlines

Arcturus Therapeutics (NASDAQ:ARCT) Shares Down 3.4%
April 6, 2021 |  americanbankingnews.com
Arcturus Therapeutics (NASDAQ:ARCT) Shares Gap Up to $38.75
March 31, 2021 |  americanbankingnews.com
Arcturus Therapeutics (NASDAQ:ARCT) Shares Down 5.9%
March 18, 2021 |  americanbankingnews.com
Arcturus Therapeutics: Q4 Earnings Insights
March 1, 2021 |  benzinga.com
Arcturus Therapeutics earnings: here's what Wall Street expects
February 27, 2021 |  markets.businessinsider.com
TransCode Therapeutics Announces Key Appointments
February 18, 2021 |  businesswire.com
See More Headlines

MarketRank

Overall MarketRank

1.60 out of 5 stars

Medical Sector

375th out of 2,011 stocks

Pharmaceutical Preparations Industry

174th out of 772 stocks

Analyst Opinion: 3.1Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
$36.97
-0.03 (-0.08 %)
(As of 04/12/2021 03:45 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ARCT News and Ratings via Email

Sign-up to receive the latest news and ratings for ARCT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Arcturus Therapeutics (NASDAQ:ARCT) Frequently Asked Questions

Is Arcturus Therapeutics a buy right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arcturus Therapeutics in the last year. There are currently 2 sell ratings, 5 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Arcturus Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ARCT, but not buy additional shares or sell existing shares.
View analyst ratings for Arcturus Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Arcturus Therapeutics?

Wall Street analysts have given Arcturus Therapeutics a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Arcturus Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Arcturus Therapeutics?

Arcturus Therapeutics saw a increase in short interest in the month of February. As of February 26th, there was short interest totaling 3,190,000 shares, an increase of 23.2% from the February 11th total of 2,590,000 shares. Based on an average daily trading volume, of 1,900,000 shares, the short-interest ratio is currently 1.7 days.
View Arcturus Therapeutics' Short Interest
.

When is Arcturus Therapeutics' next earnings date?

Arcturus Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Arcturus Therapeutics
.

How were Arcturus Therapeutics' earnings last quarter?

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) released its earnings results on Sunday, February, 28th. The biotechnology company reported ($1.25) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.88) by $0.37. The biotechnology company had revenue of $2.24 million for the quarter, compared to analyst estimates of $2.38 million. Arcturus Therapeutics had a negative trailing twelve-month return on equity of 52.32% and a negative net margin of 506.70%.
View Arcturus Therapeutics' earnings history
.

How has Arcturus Therapeutics' stock been impacted by Coronavirus (COVID-19)?

Arcturus Therapeutics' stock was trading at $13.09 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ARCT stock has increased by 179.7% and is now trading at $36.61.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for ARCT?

11 analysts have issued 12-month price objectives for Arcturus Therapeutics' stock. Their forecasts range from $31.00 to $133.00. On average, they anticipate Arcturus Therapeutics' share price to reach $70.67 in the next year. This suggests a possible upside of 93.0% from the stock's current price.
View analysts' price targets for Arcturus Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Arcturus Therapeutics' key executives?

Arcturus Therapeutics' management team includes the following people:
  • Mr. Joseph E. Payne M.Sc., Founder, Pres, CEO & Director (Age 49, Pay $693k)
  • Dr. Padmanabh Chivukula, Founder, Chief Scientific Officer, COO & Sec. (Age 42, Pay $503.2k)
  • Mr. Andrew H. Sassine, CFO & Director (Age 57, Pay $525k)
  • Mr. J.P. Headley, Associate Director of Accounting & Operations
  • Ms. Neda Safarzadeh, Director and Head of Investor Relations/PR & Marketing
  • Mr. Lance Kurata, Chief Legal Officer
  • Ms. Jessica Mendez, Associate Director of HR
  • Mr. Kevin T. Skol, Sr. VP of Bus. Devel. & Alliance Management
  • Dr. Steven George Hughes M.B.A., M.D., Chief Medical Officer (Age 53)
  • Mr. Keith C. Kummerfeld CPA, VP of Fin. & Corp. Controller

What is Joe Payne's approval rating as Arcturus Therapeutics' CEO?

9 employees have rated Arcturus Therapeutics CEO Joe Payne on Glassdoor.com. Joe Payne has an approval rating of 90% among Arcturus Therapeutics' employees.

Who are some of Arcturus Therapeutics' key competitors?

What other stocks do shareholders of Arcturus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcturus Therapeutics investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), Dynavax Technologies (DVAX), Pfizer (PFE), OPKO Health (OPK), NVIDIA (NVDA), Abbott Laboratories (ABT), CRISPR Therapeutics (CRSP) and (SNY).

What is Arcturus Therapeutics' stock symbol?

Arcturus Therapeutics trades on the NASDAQ under the ticker symbol "ARCT."

Who are Arcturus Therapeutics' major shareholders?

Arcturus Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Pacer Advisors Inc. (0.01%). Company insiders that own Arcturus Therapeutics stock include Andy Sassine, Joseph E Payne, Keith C Kummerfeld, Magda Marquet, Pad Chivukula, Peter C Farrell and Ultragenyx Pharmaceutical Inc.
View institutional ownership trends for Arcturus Therapeutics
.

Which institutional investors are buying Arcturus Therapeutics stock?

ARCT stock was acquired by a variety of institutional investors in the last quarter, including Pacer Advisors Inc.. Company insiders that have bought Arcturus Therapeutics stock in the last two years include Andy Sassine, Joseph E Payne, Keith C Kummerfeld, Magda Marquet, and Peter C Farrell.
View insider buying and selling activity for Arcturus Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Arcturus Therapeutics?

Shares of ARCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arcturus Therapeutics' stock price today?

One share of ARCT stock can currently be purchased for approximately $36.61.

How much money does Arcturus Therapeutics make?

Arcturus Therapeutics has a market capitalization of $962.11 million and generates $20.79 million in revenue each year. The biotechnology company earns $-25,990,000.00 in net income (profit) each year or ($2.15) on an earnings per share basis.

How many employees does Arcturus Therapeutics have?

Arcturus Therapeutics employs 118 workers across the globe.

What is Arcturus Therapeutics' official website?

The official website for Arcturus Therapeutics is www.arcturusrx.com.

Where are Arcturus Therapeutics' headquarters?

Arcturus Therapeutics is headquartered at 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO CA, 92121.

How can I contact Arcturus Therapeutics?

Arcturus Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-900-2660 or via email at [email protected]


This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.